NASDAQ:TENX

Tenax Therapeutics Stock Forecast, Price & News

$1.82

-0.07 (-3.70 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.80

Now: $1.82▼

$1.90

50-Day Range

$1.75

MA: $2.08▼

$2.36

52-Week Range

$0.52

Now: $1.82▼

$3.68

Volume210,999 shs

Average Volume2.28 million shs

Market Capitalization$27.24 million

P/E RatioN/A

Dividend YieldN/A

Beta2.46

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TENX

Previous Symbol

CUSIPN/A

CIK34956

Webwww.tenaxthera.com

Phone919-855-2100

Employees9

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio6.45

Quick Ratio6.45

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.56 per share

Price / Book3.25

Profitability

EPS (Most Recent Fiscal Year)($1.35)

Net Income$-8,390,000.00

Net MarginsN/A

Return on Equity-222.74%

Return on Assets-147.19%

Miscellaneous

Outstanding Shares14,969,000

Market Cap$27.24 million

Next Earnings Date5/21/2021 (Estimated)

OptionableNot Optionable

Headlines

Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected to Post Earnings of -$0.21 Per Share
April 15, 2021 | americanbankingnews.com

Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving Average of $1.69
April 15, 2021 | americanbankingnews.com

TENX: HELP Results & New Asset to Boot
April 14, 2021 | markets.businessinsider.com

4 Penny Stocks To Buy With Analysts Expecting 80%-180% Upside
April 9, 2021 | marketwatch.com

BRIEF-Tenax Therapeutics Inc Announced Publication Of Positive Data From Co's Phase 2 Help Study
April 9, 2021 | msn.com

Tenax Rises on Progress With Hypertension Treatment
April 9, 2021 | finance.yahoo.com

Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial "
April 9, 2021 | finance.yahoo.com

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual ...
April 7, 2021 | businesswire.com

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
April 7, 2021 | finance.yahoo.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Sees Significant Decline in Short Interest
April 2, 2021 | americanbankingnews.com

Tenax Therapeutics (NASDAQ:TENX) Posts Earnings Results, Misses Estimates By $0.46 EPS
April 1, 2021 | americanbankingnews.com

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update
March 31, 2021 | finance.yahoo.com

Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 4, 2021 | finance.yahoo.com

TENX: Tenax Picks Up PH Precision Med
January 20, 2021 | finance.yahoo.com

Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med
January 20, 2021 | finance.yahoo.com

Morrisville pharma makes all-stock deal for Illinois firm developing treatment for hypertension
January 20, 2021 | bizjournals.com

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
January 19, 2021 | msn.com

Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med
January 19, 2021 | finance.yahoo.com

Why Tenax Therapeutics's Stock is Trading Higher Today
December 29, 2020 | msn.com

Stock Alert: Tenax Therapeutics Surges 114%
December 29, 2020 | nasdaq.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.41 out of 5 stars

Medical Sector

649th out of 2,024 stocks

Commercial Physical Research Industry

12th out of 42 stocks

3.5 Analyst's Opinion

Consensus Rating
Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Tenax Therapeutics has a forecasted upside of 174.7% from its current price of $1.82.
Amount of Analyst Coverage
Tenax Therapeutics has received no research coverage in the past 90 days.

2.9 Community Rank

Outperform Votes
Tenax Therapeutics has received 135 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Tenax Therapeutics has received 97 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Tenax Therapeutics has received 58.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote “Outperform” if you believe TENX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Tenax Therapeutics does not currently pay a dividend.
Dividend Growth
Tenax Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.02% of the stock of Tenax Therapeutics is held by insiders.
Percentage Held by Institutions
Only 32.13% of the stock of Tenax Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Tenax Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tenax Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tenax Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tenax Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$1.82

-0.07 (-3.70 %)

(As of 04/16/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

Is Tenax Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tenax Therapeutics stock.
View analyst ratings for Tenax Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Tenax Therapeutics?

Wall Street analysts have given Tenax Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tenax Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 481,400 shares, a drop of 15.5% from the February 28th total of 569,400 shares. Based on an average trading volume of 5,110,000 shares, the short-interest ratio is presently 0.1 days.
View Tenax Therapeutics' Short Interest.

When is Tenax Therapeutics' next earnings date?

Tenax Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Tenax Therapeutics.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.46.
View Tenax Therapeutics' earnings history.

How has Tenax Therapeutics' stock price been impacted by Coronavirus?

Tenax Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TENX shares have increased by 75.0% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19.

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Tenax Therapeutics's stock reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for TENX?

1 equities research analysts have issued twelve-month price targets for Tenax Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Tenax Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price.
View analysts' price targets for Tenax Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the following people:

Mr. Anthony A. DiTonno, CEO & Director (Age 73, Pay $505.25k)
Mr. Michael B. Jebsen, Pres & CFO (Age 50, Pay $399.54k)
Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
Mr. Doug Randall, Exec. VP of Commercial & Bus. Operations
Dr. Douglas Hay, Sr. VP of Regulatory Affairs
Dr. Stuart Rich M.D., Chairman of Scientific Advisory Board, Chief Medical Officer & Director (Age 71)

Who are some of Tenax Therapeutics' key competitors?

Some companies that are related to Tenax Therapeutics include Eloxx Pharmaceuticals (ELOX), Cleveland BioLabs (CBLI), Bioqual (BIOQ), ProMIS Neurosciences (ARFXF), NanoViricides (NNVC), AIkido Pharma (AIKI), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), U.S. Stem Cell (USRM), Vitality Biopharma (VBIO), DNAPrint Genomics (DNAG), Protalex (PRTX), Affinity Energy and Health (ALGXY), Deltagen (DGEN) and Redpoint Bio (RPBC).
View all of TENX's competitors.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $1.82.

How much money does Tenax Therapeutics make?

Tenax Therapeutics has a market capitalization of $27.24 million. The specialty pharmaceutical company earns $-8,390,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Tenax Therapeutics have?

Tenax Therapeutics employs 9 workers across the globe.

What is Tenax Therapeutics' official website?

The official website for Tenax Therapeutics is www.tenaxthera.com.

Where are Tenax Therapeutics' headquarters?

Tenax Therapeutics is headquartered at ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]

This page was last updated on 4/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here